Veterinary Medicines

Jodofoam Endofoam 0,2/0,4g intrauterina pjena, za goveda (krave)

Authorised
  • Iodine
  • Potassium iodide
Download as PDF

Product identification

Medicine name:
Jodofoam Endofoam 0,2/0,4g intrauterina pjena, za goveda (krave)
Active substance:
  • Iodine
  • Potassium iodide
Target species:
  • Cattle (cow)
Route of administration:
  • Intrauterine use

Product details

Active substance and strength:
  • Iodine
    0.20
    gram(s)
    /
    45.20
    gram(s)
  • Potassium iodide
    0.40
    gram(s)
    /
    45.20
    gram(s)
Pharmaceutical form:
  • Intrauterine foam
Withdrawal period by route of administration:
  • Intrauterine use
    • Cattle (cow)
      • Meat and offal
        0
        day
      • Milk
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QG51AD30
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Croatia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Fortevit Kft.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Pernix Pharma Kft.
Responsible authority:
  • Ministry Of Agriculture Veterinary And Food Safety Directorate
Authorisation number:
  • UP/I-322-05/21-01/753
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Croatian (PDF)
Published on: 26/03/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."